• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

    IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

    /DISREGARD RELEASE: M4Markets/

    GENAI Summit 2025: Forging a Network of AI Innovators

    GENAI Summit 2025: Forging a Network of AI Innovators

    New DJI Power 1000 V2 Increases Stable Power Output for a Smarter, More Efficient Experience

    New DJI Power 1000 V2 Increases Stable Power Output for a Smarter, More Efficient Experience

    Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

    Sale of Green Form flats announced

    Sale of Green Form flats announced

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Medisafe Scandal Deepens as HK Institutions Deny Outsourcing, Despite Contradictory Interview, Vendor Evidence and Whistleblower Claims

    Geneva Invention Awards Respond to Medisafe Scandal: ‘We Will Engage Our Own Panel to Determine Any Action’

    Deloitte: Over 40% of Family Offices Prioritise Tech Amid Digital Transformation

    PwC: AI-Exposed Jobs See Surge in Demand, Pay, and Productivity

    PwC: AI-Exposed Jobs See Surge in Demand, Pay, and Productivity

    Hong Kong Student Criticised for Using Outsourced AI Project to Win STEM Awards

    Xiaomi SU7 Ultra Becomes Fastest Mass-Produced EV on Nürburgring Nordschleife

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

    IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

    /DISREGARD RELEASE: M4Markets/

    GENAI Summit 2025: Forging a Network of AI Innovators

    GENAI Summit 2025: Forging a Network of AI Innovators

    New DJI Power 1000 V2 Increases Stable Power Output for a Smarter, More Efficient Experience

    New DJI Power 1000 V2 Increases Stable Power Output for a Smarter, More Efficient Experience

    Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial

    Sale of Green Form flats announced

    Sale of Green Form flats announced

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Medisafe Scandal Deepens as HK Institutions Deny Outsourcing, Despite Contradictory Interview, Vendor Evidence and Whistleblower Claims

    Geneva Invention Awards Respond to Medisafe Scandal: ‘We Will Engage Our Own Panel to Determine Any Action’

    Deloitte: Over 40% of Family Offices Prioritise Tech Amid Digital Transformation

    PwC: AI-Exposed Jobs See Surge in Demand, Pay, and Productivity

    PwC: AI-Exposed Jobs See Surge in Demand, Pay, and Productivity

    Hong Kong Student Criticised for Using Outsourced AI Project to Win STEM Awards

    Xiaomi SU7 Ultra Becomes Fastest Mass-Produced EV on Nürburgring Nordschleife

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News PR Newswire

A Visionary Breakthrough: VISTA Eye Specialist and EssilorLuxottica Join Forces to Combat Childhood Myopia in Malaysia

PR Newswire by PR Newswire
25 April 2025
in PR Newswire
0
A Visionary Breakthrough: VISTA Eye Specialist and EssilorLuxottica Join Forces to Combat Childhood Myopia in Malaysia
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

PETALING JAYA, Malaysia, April 25, 2025 /PRNewswire/ — In a landmark move to safeguard the vision of Malaysia’s future generation, VISTA Eye Specialist (‘VISTA’), the nation’s trusted eye care brand, announced a strategic collaboration Memorandum of Understanding (MoU) with EssilorLuxottica, the global leader in Medtech for vision care.

VISTA Eye Specialist signs MoU with EssilorLuxottica Malaysia to strengthen efforts against childhood myopia.
VISTA Eye Specialist signs MoU with EssilorLuxottica Malaysia to strengthen efforts against childhood myopia.

This partnership heralds a nationwide initiative to tackle the silent epidemic of childhood myopia, combining clinical excellence, global innovation, and a deep commitment to community health.

Myopia: More Than Just Blurry Vision

Myopia (short-sightedness) is emerging as a significant public health concern. Left unmanaged, it doesn’t just require glasses with higher prescriptions. It opens the door to a lifetime of serious vision-threatening complications[1&2], therefore myopia management from an early age is critical[3].

“The world sees myopia as a childhood inconvenience. But unchecked, it becomes a lifetime disability,” said Lim Boon Siong, Director of VISTA Eye Specialist. “Our children deserve better—and we’re stepping up.”

The Hidden Dangers of High Myopia[1]:

  • Retinal Detachment – Eye elongation can stretch and thin the retina, leading to tears or detachment that may cause sudden, irreversible blindness.
  • Myopic Macular Degeneration (MMD) – A leading cause of permanent central vision loss, especially in adults who were highly myopic as children.
  • Glaucoma – Myopic eyes are more vulnerable to this “silent thief of sight”, which causes progressive, irreversible damage to the optic nerve.
  • Early Cataracts – High myopia increases the risk of early-onset cataracts, which often require surgery earlier in life.

By 2050, it’s projected that 1 in 2 people globally will be myopic[2]. In parts of Asia, including Malaysia, up to 80–90% of schoolchildren already show signs of myopia. The time to act is now.

VISTA & EssilorLuxottica: A United Vision

Through this MoU, VISTA and EssilorLuxottica commit to an ambitious, multi-pronged strategy:

EssilorLuxottica Malaysia will:

  • Lead nationwide myopia management educational and awareness campaigns—including webinars, digital content, and parent workshops—to empower families with crucial knowledge about myopia prevention myopia management and control.

VISTA Eye Specialist will:

  • Deliver comprehensive myopia screenings through its extensive network of centers
  • Establish a referral program to connect diagnosed children with tailored myopia management solutions
  • Launch a CSR campaign starting with a free eye clinic for 200 underprivileged children, supported by volunteers from the OneSight EssilorLuxottica Foundation
  • Expand outreach to include adults and seniors, fostering lifelong eye health for all

“This is about safeguarding vision and reduce the risk of severe eye conditions linked to high myopia,” said Denis Chng, Country Manager of EssilorLuxottica Malaysia. “We have to act now—healthy eyes today ensure clear sight for a lifetime!”

Looking Ahead: Hope in Sight

This collaboration marks just the beginning. Both organizations aim to scale this initiative across Malaysia—from cities to underserved rural communities. Their shared goal is to drastically reduce the incidence and impact of myopia by prioritizing early intervention, education on myopia management, and access to vision care.

About VISTA Eye Specialist

Established in 1999, VISTA Eye Specialist is Malaysia’s most trusted name in eye care. VISTA was recently honored with Newsweek’s Asia’s Top Private Hospital Awards 2025, recognizing its dedication to clinical excellence, innovation, and patient satisfaction. With a strong presence across the country and more than 460,000 satisfied patients, VISTA is renowned for its excellence in LASIK, cataract, and myopia control services. VISTA’s commitment goes beyond treatment—it is about transforming lives through vision.

About EssilorLuxottica

EssilorLuxottica is a global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses. With over 200,000 employees across 150 countries, 650 operations facilities and 18,000 stores, in 2023 the Company generated consolidated revenue of Euro 25.4 billion. Its mission is to help people around the world to see more and be more by addressing their evolving vision needs and personal style aspirations. EssilorLuxottica is home to the most advanced lens technologies including Varilux, Stellest and Transitions, the most iconic eyewear brands including Ray-Ban and Oakley, the most desired luxury licensed brands and world-class retailers including LensCrafters and Sunglass Hut. The Company’s OneSight EssilorLuxottica Foundation has given access to sustainable vision care to more than 760 million people in underserved communities. 

Reference

  1. Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, Klaver CCW. The Complications of         Myopia: A Review and Meta-Analysis. Invest Ophthalmol Vis          Sci. 2020;61(4):49. doi:10.1167/iovs.61.4.49
  2. Holden BA,      Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High           Myopia and Temporal Trends from 2000 through 2050. Ophthalmology.             2016;123(5):1036-1042. doi:10.1016/j.ophtha.2016.01.006
  3. K. Zadnik, G.L. Mitchell, L.A. Jones, D.O. Mutti; Factors Associated with    Rapid Myopia Progression in School–aged Children . Invest.       Ophthalmol. Vis. Sci. 2004;45(13):2306.

 

Tags: prnewswire
PR Newswire

PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

Read More

IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

9 July 2025

/DISREGARD RELEASE: M4Markets/

9 July 2025
  • Trending
  • Comments
  • Latest
Hasten Accelerates Asia-Pacific Expansion with Successful MAT Transfers of 11 Products

Hasten Accelerates Asia-Pacific Expansion with Successful MAT Transfers of 11 Products

16 June 2025

Hong Kong Student Criticised for Using Outsourced AI Project to Win STEM Awards

16 June 2025
Southbound travel plan announced

Southbound travel plan announced

2 July 2025
FORTUNE UNVEILS 2025 SOUTHEAST ASIA 500

FORTUNE UNVEILS 2025 SOUTHEAST ASIA 500

17 June 2025
IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

9 July 2025

/DISREGARD RELEASE: M4Markets/

9 July 2025
GENAI Summit 2025: Forging a Network of AI Innovators

GENAI Summit 2025: Forging a Network of AI Innovators

9 July 2025
New DJI Power 1000 V2 Increases Stable Power Output for a Smarter, More Efficient Experience

New DJI Power 1000 V2 Increases Stable Power Output for a Smarter, More Efficient Experience

9 July 2025

Recent News

IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

IASO Bio Receives Orphan Drug Designation from the Ministry of Food and Drug Safety of South Korea for Equecabtagene Autoleucel

9 July 2025

/DISREGARD RELEASE: M4Markets/

9 July 2025
GENAI Summit 2025: Forging a Network of AI Innovators

GENAI Summit 2025: Forging a Network of AI Innovators

9 July 2025
New DJI Power 1000 V2 Increases Stable Power Output for a Smarter, More Efficient Experience

New DJI Power 1000 V2 Increases Stable Power Output for a Smarter, More Efficient Experience

9 July 2025
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com